Equillium (EQ) Net Margin (2023 - 2024)
Equillium's (EQ) quarterly Net Margin came in at 132.81% in Q4 2024, down 9412.0% year-on-year from 1.43% in Q1 2024, and down 230628.31% on a QoQ basis from 0.06% in Q3 2024.
Equillium (EQ) Net Margin (2023 - 2024) Analysis & Trends
Equillium (EQ) has 2 years of Net Margin data on file, last reported at 132.81% in Q4 2024.
- On a quarterly basis, Net Margin fell 9412.0% year-over-year to 132.81% in Q4 2024; TTM through Sep 2025 was 670.67%, a 65796.0% decrease from a year earlier, with the FY2024 full-year figure at 19.73%, up 2062.0% from the prior year.
- Net Margin for Q4 2024 stood at 132.81%, down from 0.06% in the prior quarter.
- Over the last five years, Net Margin for EQ reached as high as 3.38% in Q2 2024 and fell as low as 132.81% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 15.02% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 28.20% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Equillium | 242.14 Mn | 242.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -132.81% |
| Sep 30, 2024 | -0.06% |
| Jun 30, 2024 | 3.38% |
| Mar 31, 2024 | -25.58% |
| Dec 31, 2023 | -38.69% |
| Sep 30, 2023 | -41.83% |
| Jun 30, 2023 | -36.64% |
| Mar 31, 2023 | -44.37% |